ArticleNeuropharmacology2020
Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABA
Open access · hybridAbstract read
In one paragraph
Article in Neuropharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 4 pooled it
6.5field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 4 syntheses or guidelines pooled it, 121 citations in OpenAlex.
- The efficacy and safety of Zuranolone for treatment of depression: A systematic review and meta-analysis.Psychopharmacology · 2024Pooled it
- Evaluating the safety and efficacy of zuranolone in the management of major depressive disorder and postpartum depression, with or without concurrent insomnia: a rigorous systematic review and meta-analysis.Frontiers in psychiatry · 2024Pooled it
- Zuranolone for treatment of major depressive disorder: a systematic review and meta-analysis.Frontiers in neuroscience · 2024Pooled it
- Investigational Drugs for the Treatment of Depression (Part 1): Monoaminergic, Orexinergic, GABA-Ergic, and Anti-Inflammatory Agents.Frontiers in pharmacology · 2022Pooled it
- Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double-blind, randomized, placebo-controlled, Phase 3 clinical trial.Psychiatry and clinical neurosciences · 2026Trial
- An open-label, proof-of-mechanism trial evaluating a neuroactive steroid GABA modulator in tinnitus.Frontiers in neurology · 2025Trial
- Cognitive effects, pharmacokinetics, and safety of zuranolone administered alone or with alprazolam or ethanol in healthy adults in a phase 1 trial.Journal of psychopharmacology (Oxford, England) · 2024Trial
- Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Trial
- Pharmacokinetics, safety, and tolerability of single and multiple doses of zuranolone in Japanese and White healthy subjects: A phase 1 clinical trial.Neuropsychopharmacology reports · 2023Trial
- Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial.JAMA psychiatry · 2021Trial
- Article
- Zuranolone in Postpartum Depression: Mechanistic Innovation, Clinical Evidence, and Translational Uncertainty.Cureus · 2026Review
- Associations of Allopregnanolone and Related Steroid Hormones with Prenatal Psychosocial Distress in the Healthy Start Cohort.medRxiv : the preprint server for health sciences · 2026Article
- Response to Durability of zuranolone in postpartum depression versus major depressive disorder.Psychiatry and clinical neurosciences · 2026Article
- First Reported Case of Dissociative Symptoms Associated With Zuranolone Use in Peripartum Depression.Cureus · 2026Article
- Zuranolone mitigates delirium-like bispectral EEG changes, behavioral deficits, and neuroinflammation across surgical and inflammatory mouse models and age groups.bioRxiv : the preprint server for biology · 2026Article
- GABAergic Neuroactive Steroids and Network States: Relevance to Peripartum Depression.Biological psychiatry · 2026Review
- Review
- Maternal Milk Allopregnanolone May Buffer Negative Associations Between Maternal Postpartum Psychological Distress and Infant Regulatory Capacity.Developmental psychobiology · 2026Article
- Safety and efficacy of zuranolone in Japanese adults with major depressive disorder: An open-label, repeated-treatment part of a Phase 3 clinical trial.PCN reports : psychiatry and clinical neurosciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 1 country.
Alison L AlthausResearch and Nonclinical Development, Sage Therapeutics, Inc., Cambridge, MA, USA. Electronic address: alison.althaus@sagerx.com.
Michael A AckleyResearch and Nonclinical Development, Sage Therapeutics, Inc., Cambridge, MA, USA.
Gabriel M BelfortResearch and Nonclinical Development, Sage Therapeutics, Inc., Cambridge, MA, USA.
Steven M GeeResearch and Nonclinical Development, Sage Therapeutics, Inc., Cambridge, MA, USA.
Jing DaiResearch and Nonclinical Development, Sage Therapeutics, Inc., Cambridge, MA, USA.
David P NguyenResearch and Nonclinical Development, Sage Therapeutics, Inc., Cambridge, MA, USA.
Tatiana M KazdobaResearch and Nonclinical Development, Sage Therapeutics, Inc., Cambridge, MA, USA.
Amit ModgilDepartment of Neuroscience, Tufts University, Boston, MA, USA.
Paul A DaviesDepartment of Neuroscience, Tufts University, Boston, MA, USA.
Stephen J MossDepartment of Neuroscience, Tufts University, Boston, MA, USA.
Francesco G SalituroResearch and Nonclinical Development, Sage Therapeutics, Inc., Cambridge, MA, USA.
Ethan HoffmannResearch and Nonclinical Development, Sage Therapeutics, Inc., Cambridge, MA, USA.
Rebecca S HammondResearch and Nonclinical Development, Sage Therapeutics, Inc., Cambridge, MA, USA.
Albert J RobichaudResearch and Nonclinical Development, Sage Therapeutics, Inc., Cambridge, MA, USA.
Michael C QuirkResearch and Nonclinical Development, Sage Therapeutics, Inc., Cambridge, MA, USA.
James J DohertyResearch and Nonclinical Development, Sage Therapeutics, Inc., Cambridge, MA, USA.
Sage Therapeutics (United States) · USTufts University · US
Funding
Mechanisms that determine Glutamine synthetase activity in the brainR01NS081986 · NINDS · TUFTS UNIVERSITY BOSTON · PI MOSS, STEPHEN J · 2012 to 2022
$3.7MNovel actions of neurosteroids on GABA (A) receptor traffickingR01NS108378 · NINDS · TUFTS UNIVERSITY BOSTON · PI DAVIES, PAUL ANDREW, MOSS, STEPHEN J · 2018 to 2022
$2.0MDetermining the effects of human KCC2 mutations on neuronal excitabilityR21NS111338 · NINDS · TUFTS UNIVERSITY BOSTON · PI DAVIES, PAUL ANDREW · 2019 to 2020
$454kSensory Hypersensitivity in Fragile X Syndrome Due to Deficits in Tonic Inhibition Reversed by Neuroactive SteroidsR21NS111064 · NINDS · TUFTS UNIVERSITY BOSTON · PI DAVIES, PAUL ANDREW · 2020 to 2021
$450kNINDS NIH HHS R01 NS081986NINDS NIH HHS R01 NS108378NINDS NIH HHS R21 NS111064NINDS NIH HHS R21 NS111338
Abstract
Zuranolone (SAGE-217) is a novel, synthetic, clinical stage neuroactive steroid GABA
Indexed as
AnimalsAnticonvulsantsAntidepressive AgentsBinding SitesBrainDiazepamDrug SynergismElectroencephalographyGABA-A Receptor AgonistsGABA Modulatorsgamma-Aminobutyric AcidHippocampusHumansMaleMicePregnanesAnticonvulsantsAntidepressive AgentsDiazepamGABA-A Receptor AgonistsGABA Modulatorsgamma-Aminobutyric AcidPregnanesPregnanolonePyrazolesReceptors, GABASteroidszuranoloneGABA(A) receptorNeuroactive steroidPositive allosteric modulator
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.